Navigation Links
Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
Date:12/6/2009

44 and using the passcode 25914947 later in the day. The replay will be available on the Onyx website through January 7, 2010.

About Carfilzomib

Carfilzomib is a selective, next generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma. Carfilzomib is currently undergoing evaluation as a single agent in multiple Phase 2 and Phase 1 clinical trials in relapsed or refractory multiple myeloma. These trials include a Phase 2b monotherapy study in patients with relapsed, refractory multiple myeloma, the pivotal trial that could support a new drug application (NDA) filing by the end of 2010. Carfilzomib is also being evaluated in advanced solid tumors.

About Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with MM and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with MM and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(® )(sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
2. More proof needed of safety and quality of electronic personal health records
3. Back to School Means Backpack Safety
4. Seniors Need a Safety Plan in Face of Disasters
5. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
6. National Patient Safety Foundation Partners with Vocera Communications
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
(Date:10/22/2014)... October 22, 2014 With the Affordable Care ... survey by the American Institutes for Research (AIR) finds that ... to use health insurance, but 42 percent say they are ... details before signing up for coverage. , The AIR survey ... 20 percent able to calculate correctly how much they owe ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... health officials on Monday officially tightened guidelines for health workers ... skin exposure and use of a respirator at all times. ... to issue the tougher rules after two Dallas nurses contracted ... the United States, Liberian national Thomas Eric Duncan. Nina Pham ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... microscope, scientists have tried to visualize smaller and smaller structures ... bacteria and viruses. Now, researchers at the National Institute ... the National Institutes of Health, have developed a new way ... before. Their findings are reported in the Jan. 13 ...
... (HealthDay News) -- The chemotherapy used to treat a form ... the return of the disease within years, a new study ... who thought chemotherapy drugs could disrupt DNA through mutations and ... medications. "Chemotherapy drugs are absolutely necessary to get ...
... Jefferson,s Kimmel Cancer Center has started a ... cancer chemotherapy drug to extend survival, Cabazitaxel, in ... approach could improve disease control and eventually survival ... single-center, open-label, non-randomized Phase I study ...
... Using two cell surface markers found to be ... researchers at Moffitt Cancer Center, working with colleagues ... imaging probes that can non-invasively detect breast cancer ... breast cancer patients invasive and unreliable sentinel lymph ...
... women are scarce leads men to become impulsive, save less, ... of Minnesota,s Carlson School of Management. "What we see ... become more competitive. They compete more for access to mates," ... Carlson School and lead author of the study. "How do ...
... language are quicker at recognizing and interpreting body language than ... Davis and UC Irvine. The work suggests that deaf ... visual traits in the actions of others, an ability that ... screening. "There are a lot of anecdotes about deaf ...
Cached Medicine News:Health News:NIH scientists identify novel approach to view inner workings of viruses 2Health News:DNA Damage From Chemo May Help Spur Leukemia's Return 2Health News:Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival 2Health News:Researchers find new, noninvasive way to identify lymph node metastasis 2Health News:A scarcity of women leads men to spend more, save less 2Health News:A scarcity of women leads men to spend more, save less 3Health News:Deaf sign language users pick up faster on body language 2
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... BOSTON, Nov. 26 Surface Logix, Inc. today announced,that ... an,update of the company,s drug development pipeline at the ... 27-29, 2007 at The,Pierre Hotel in New York City. ... 2007 at 2:50 PM EST., Surface Logix currently ...
... GAITHERSBURG, Md., Nov. 26 MedImmune, Inc. today,announced ... first Phase 1 clinical,trial of CAM- 3001, a ... of the granulocyte-macrophage colony stimulating factor,receptor (GM-CSFR). The ... of single doses of CAM-3001 in patients with ...
Cached Medicine Technology:MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Medicine Products: